Literature DB >> 3486688

Postjunctional inhibition of contractor responses in the mouse vas deferens by rat and human calcitonin gene-related peptides (CGRP).

S J Al-Kazwini, R K Craig, I Marshall.   

Abstract

The effects of rat and human alpha-calcitonin gene-related peptide (CGRP) were compared in the mouse and rabbit isolated vas deferens preparation contracted by either field stimulation or acetylcholine. The peptides were about equipotent at inhibiting twitch responses of the mouse vas deferens to field stimulation at 0.2 Hz (IC50 12 +/- 4 nM and 15 +/- 3 nM, rat and human alpha-CGRP respectively). Rat alpha-CGRP was less potent at inhibiting responses to 10 Hz than to either 0.2 Hz or 1.0 Hz stimulation. The potency of rat alpha-CGRP at 1.0 Hz was unaltered by halving the calcium concentration of the Krebs solution. The inhibitory effect of human alpha-CGRP was not antagonized by either propranolol (300 nM) or idazoxan (300 nM), although in the same tissues these latter two drugs reduced responses to isoprenaline and clonidine respectively. Rat alpha-CGRP (100 nM) and human alpha-CGRP (1.0 microM) did not alter the uptake of [3H]-noradrenaline (30 nM) into mice isolated vasa deferentia. Rat alpha-CGRP (3-100 nM) did not alter the fractional release per pulse (1.0 Hz, 100 pulses) of tritium from vasa preloaded with [3H]-noradrenaline, although at the same time the peptide inhibited responses of the smooth muscle to field stimulation. Rat and human alpha-CGRP were equipotent at inhibiting contractions of the mouse vas deferens evoked by acetylcholine although the peptides were less potent than against twitch responses. In the rabbit vas deferens neither rat nor human alpha-CGRP (3 nM-1 microM) inhibited either twitch responses or acetylcholine contractions. 7 These results suggest that rat and human alpha-CGRP inhibit contractor responses of the mouse vas deferens not by interference with adrenergic mechanisms, but through postjunctional (possibly CGRP) receptors. A similar mechanism may underlie effects ofCGRP in other tissues. The rabbit vas deferens appears to lack the CGRP 'receptors'.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486688      PMCID: PMC1917096          DOI: 10.1111/j.1476-5381.1986.tb09484.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function.

Authors:  J M Lundberg; L Terenius; T Hökfelt; C R Martling; K Tatemoto; V Mutt; J Polak; S Bloom; M Goldstein
Journal:  Acta Physiol Scand       Date:  1982-12

2.  Alternative RNA processing: determining neuronal phenotype.

Authors:  M G Rosenfeld; S G Amara; R M Evans
Journal:  Science       Date:  1984-09-21       Impact factor: 47.728

3.  Calcitonin gene related peptide coding sequence is conserved in the human genome and is expressed in medullary thyroid carcinoma.

Authors:  P H Steenbergh; J W Höppener; J Zandberg; W J Van de Ven; H S Jansz; C J Lips
Journal:  J Clin Endocrinol Metab       Date:  1984-08       Impact factor: 5.958

4.  Calcitonin gene-related peptide: potent peripheral inhibitor of gastric acid secretion in rats and dogs.

Authors:  Y Taché; T Pappas; M Lauffenburger; Y Goto; J H Walsh; H Debas
Journal:  Gastroenterology       Date:  1984-08       Impact factor: 22.682

5.  Structure and expression of a gene encoding human calcitonin and calcitonin gene related peptide.

Authors:  B D Nelkin; K I Rosenfeld; A de Bustros; S S Leong; B A Roos; S B Baylin
Journal:  Biochem Biophys Res Commun       Date:  1984-09-17       Impact factor: 3.575

6.  Neuropeptide Y (NPY) depresses the secretion of 3H-noradrenaline and the contractile response evoked by field stimulation, in rat vas deferens.

Authors:  J M Lundberg; L Stjarne
Journal:  Acta Physiol Scand       Date:  1984-03

7.  Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptide.

Authors:  L A Fisher; D O Kikkawa; J E Rivier; S G Amara; R M Evans; M G Rosenfeld; W W Vale; M R Brown
Journal:  Nature       Date:  1983 Oct 6-12       Impact factor: 49.962

8.  Isolation and characterization of human calcitonin gene-related peptide.

Authors:  H R Morris; M Panico; T Etienne; J Tippins; S I Girgis; I MacIntyre
Journal:  Nature       Date:  1984 Apr 19-25       Impact factor: 49.962

9.  The effects of pancreatic polypeptides and neuropeptide Y on the rat vas deferens.

Authors:  T Ohhashi; D M Jacobowitz
Journal:  Peptides       Date:  1983 May-Jun       Impact factor: 3.750

10.  Two novel related peptides, neuropeptide Y (NPY) and peptide YY (PYY) inhibit the contraction of the electrically stimulated mouse vas deferens.

Authors:  J M Allen; T E Adrian; K Tatemoto; J M Polak; J Hughes; S R Bloom
Journal:  Neuropeptides       Date:  1982-12       Impact factor: 3.286

View more
  5 in total

Review 1.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 2.  CGRP and its receptors provide new insights into migraine pathophysiology.

Authors:  Tony W Ho; Lars Edvinsson; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2010-09-07       Impact factor: 42.937

3.  Central cardiovascular effects of calcitonin gene-related peptide: interaction with noradrenaline in the nucleus tractus solitarius of rats.

Authors:  M Vallejo; S Lightman; I Marshall
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

4.  Human alpha-calcitonin gene-related peptide (CGRP) is a potent vasodilator in human mesenteric vasculature.

Authors:  I Marshall; S J Al-Kazwini; J J Holman; R K Craig
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

5.  Demonstration of the neurotransmitter role of calcitonin gene-related peptides (CGRP) by immunoblockade with anti-CGRP monoclonal antibodies.

Authors:  K K Tan; M J Brown; J Longmore; C Plumpton; R G Hill
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.